ADVFN - Advanced Financial Network.
HOME» NASDAQ » A » AMGN Stock Price » AMGN Stock News

Amgen Inc. Share News

 Amgen Inc. (mm) Stock Price
AMGN Stock Price
 Amgen Inc. (mm) Stock Chart
AMGN Stock Chart
 Amgen Inc. (mm) Stock News
AMGN Stock News
 Amgen Inc. (mm) Company Information
AMGN Company Information
 Amgen Inc. (mm) Stock Trades
AMGN Stock Trades

Bayer To Develop Cancer Treatment With Amgen

FRANKFURT -(Dow Jones)- German chemical and pharmaceutical company Bayer AG (BAYN.XE) said Tuesday it has agreed with Amgen Inc. (AMGN) to develop and commercialize a new antibody for treating cancer. MAIN FACTS: -Financial details of the deal weren't disclosed. -Bayer will collaborate with Amgen at its Munich site from the research phase to the completion of initial clinical trials. -After the initial trials have been completed, Bayer will be responsible for further development and commercialization of the product candidate. -In 2009, Bayer had entered into an agreement with Micromet, Inc. to produce another antibody. -Micromet was acquired by Amgen in early 2012. -Frankfurt Bureau, Dow Jones Newswires; 49-69-29725-500

Stock News for Amgen Inc. (AMGN)
DateTimeHeadline
12/09/201617:14:41Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)
12/02/201616:00:00Amgen Announces Launch Of Blood Counts™ And Collaboration With S...
12/02/201609:00:00Amgen And Allergan Submit Biosimilar Marketing Authorization...
12/01/201616:00:00Amgen To Present At The Citi 2016 Global Healthcare Conference
11/30/201618:31:00The Lancet Publishes Results From COSMIC-HF Trial Showing Omecamtiv...
11/30/201618:30:00The Lancet Publishes Results From COSMIC-HF Trial Showing Omecamtiv...
11/30/201610:00:00Amgen Announces Presentation Of New Data In Acute Lymphoblastic...
11/16/201616:30:00Amgen Announces Erenumab Significantly Reduces Monthly Migraine...
11/15/201616:00:00Amgen And Allergan Submit Biosimilar Biologics License Application...
11/15/201612:28:00Repatha® (Evolocumab) Regresses Atherosclerosis In Patients...
11/14/201609:00:00New 'Ten To Watch' List Highlights Top Amgen Scholars Poised...
11/12/201616:30:00Results From Phase 3 BRIDGE Study Show Romosozumab Significantly...
11/11/201616:00:00European Commission Approves Parsabiv™ (etelcalcetide) For T...
11/10/201616:00:00Amgen To Webcast Investor Meeting At Upcoming American Heart...
11/10/201608:33:00Amgen Announces Collaboration With Janssen To Co-Fund Studies...
11/07/201616:00:00Data To Be Presented At ACR/ARHP 2016 Annual Meeting Show Amgen's...
11/04/201617:26:00FDA Approves Expanded Use Of ENBREL® (etanercept) To Treat Children...
11/04/201608:50:00Regeneron Revenue Growth Slows
11/03/201617:25:27Statement of Changes in Beneficial Ownership (4)
11/03/201616:01:00Amgen To Present At The Credit Suisse 25th Annual Healthcare...

Amgen Inc. and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2016 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US